A federal jury in the United States District Court for the District of Maryland unanimously ruled on Nov. 18 in favor of myself and ExeGi Pharma, which distributes my Formulation in the US, against VSL Inc, Leadiant and Alfasigma, for False Advertising, Unjust Enrichment and Unpaid Royalties.

The jury unanimously found that the defendant pharmaceutical companies must pay a total of more than $18 million in compensatory damages, including $15 million for violation of the Lanham Act by deceiving patients, physicians, and other stakeholders concerning the probiotic VSL#3® they have been marketing since 2016.

The De Simone Formulation is exclusively available under the brand Visbiome in the USA and Vivomixx in Europe.

Read the Press Release of the commercial litigators Schulman Bhattacharya, the lawyers of Professor De Simone and Exegi Pharma:

It has been made clear that VSL Pharmaceuticals had attempted to create a “knock-off” product, even though they never had access to my proprietary formula which has been studied in over 60 clinical trials.

Pr De Simone, About

Share this article!

Keep connected, Subscribe